Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

KDTV001 Injection in Patients With Human Papillomavirus (HPV) Types 16, and/or 18, and/or 52 Associated Cervical High-Grade Squamous Intraepithelial Lesion .

13 de novembro de 2026 atualizado por: Wuhan KadGeno Biotechnology Co., Ltd

Phase 1/2, Multi-center, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Immunogenicity and Preliminary Efficacy of KDTV001 Injection in Patients With Human Papillomavirus (HPV) Types 16, and/or 18, and/or 52 Associated Cervical High-Grade Squamous Intraepithelial Lesion .

KDTV001 Injection is a non-replicating adenovirus serotype 5 (Ad5)-based therapeutic HPV vaccine developed by Wuhan KadGeno Biotechnology Co., Ltd. It utilizes an engineered adenoviral vector expressing the HPV16/18/52 E6/E7 fusion protein under CMV promoter control, designed to inducing a robust cellular immune response that eradicates HPV-related lesions.

This is a Phase I, multicenter, open-label, dose-escalation and expansion study to evaluate the safety, tolerability, immunogenicity, and preliminary efficacy of KDTV001 Injection in participants with HPV types 16, and/or 18, and/or 52-associated cervical HSIL.

The study consists of three parts: dose escalation, an immunogenicity expansion cohort (Phase 1), and a dose expansion phase (Phase 2). In Phase 1a, 3+3 dose escalation of KDTV001 Injection will be conducted separately for IM and IC administration, with two ascending dose levels evaluated for each route. During the dose-escalation phase, if a dose cohort is assessed as safe by SRC, an immunogenicity expansion of 10-20 participants may be conducted. Based on Phase 1 safety and immunogenicity data, 1-2 dose levels will be selected for Phase 2 dose expansion for both IC and IM. In the Phase 2 dose-expansion phase, each dose cohort will enroll 30-50 participants. Both phases will consist of a screening period, a treatment and safety follow-up period, an end of study visit (EOS) and a long-term follow-up period.

Visão geral do estudo

Status

Recrutamento

Condições

Intervenção / Tratamento

Tipo de estudo

Intervencional

Inscrição (Estimado)

304

Estágio

  • Fase 2
  • Fase 1

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

  • Nome: Yanyan Zhang, MMed
  • Número de telefone: +8618607163222
  • E-mail: Linda@whkdws.com

Locais de estudo

    • Hubei
      • Wuhan, Hubei, China
        • Recrutamento
        • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
        • Investigador principal:
          • Peng Wu, Prof
      • Wuhan, Hubei, China
        • Recrutamento
        • TongJi Hospital, Tongji Medical College, Huazhong University of Science and Technology
        • Contato:
          • Nan Yu, Prof
        • Investigador principal:
          • Nan Yu, Prof
        • Investigador principal:
          • Gang Chen, Prof

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Fêmea

Descrição

Inclusion Criteria:

  • Cervical HSIL (defined as CIN 2 or 3), with the histological diagnosis confirmed by central pathology review within 12 weeks before the first study dose. Note: CIN 3 patients for whom immediate lesion removal is recommended by a clinician will not be enrolled in this study.
  • Confirmed cervical infection with HPV types 16, and/or 18, and/or 52 at screening by Central Lab. If there are other high-risk types of HPV infection, the investigator should assess based on the participant's infection history to exclude cases where such non-target types are persistent infections and the primary causes of disease.
  • All participants must have lesions of adequate size to ensure that a visible lesion remains after the screening biopsy.
  • Participants must have satisfactory colposcopy at screening, defined as full visualization of entire lesion and the squamo-columnar junction (Type I or II transformation zone).
  • Female participants aged ≥ 18 years.
  • No significant impairment of major organ functions, including but not limited to hematopoietic, cardiac, pulmonary, hepatic, and renal functions.
  • Female participants must meet one of the following criteria with respect their reproductive capacity:

a Post-menopausal as defined by spontaneous amenorrhea for more than 12 months; b Surgically sterile due to absence of ovaries or due to a bilateral tubal ligation/occlusion performed more than 12 months prior to screening; c Women of Child Bearing Potential (WOCBP) must have a negative serum pregnancy test during the screening period; participants must agree to use reliable contraceptive methods (barrier methods or abstinence) with their partners during the study and for at least 12 months after the last dose of investigational product.

- Be willing to participate in this study and provide a signed informed consent form prior to participating in the trial.

Exclusion Criteria:

  • Cervical adenocarcinoma in situ (AIS), atypical endometrial or glandular cells, or histopathological evidence of invasive cervical carcinoma on cervical biopsy within 12 weeks prior to the first study dose.

  • Have received pelvic radiotherapy within the past five years.

  • Have any active infection requiring systemic anti-infective treatment (routine prophylactic anti-infective treatment per the clinical trial institution is allowed) or an unexplained fever >38.5°C during the screening period.

  • Have more than three episodes of abnormal uterine bleeding within the recent three months.

  • Have a history of receiving adenovirus-based therapies within 6 months.

  • Participants with symptomatic vaginitis, including but not limited to bacterial, fungal, or trichomonal vaginitis. Participants may be eligible for enrollment after satisfactory treatment.

  • Participants who are pregnant, lactating, or unwilling to use protocol-defined contraception at any time during the study;

  • History of other organ systems malignancies within the past five years, which in the investigator's judgment may interfere with study conduct or require systemic anticancer therapy during the study.

  • Poorly controlled diabetes (defined as fasting blood glucose ≥ 10 mmol/L) despite medication at screening.

  • Major surgery within 4 weeks prior to the first dose or anticipated during the study (excluding diagnostic procedures). Participants must have fully recovered from the toxicities and/or complications of the prior major surgery if conducted more than 4 weeks prior to the first study dose.

  • Participants with hereditary bleeding diathesis or coagulopathy, history of thrombosis or hemorrhage, or requirement for chronic anticoagulant therapy.

  • Have a history of severe cardiovascular or cerebrovascular diseases, including but not limited to:

    1. Severe cardiac conduction abnormalities requiring clinical intervention (e.g. ventricular arrhythmias requiring treatment, second- or third-degree atrioventricular block).
    2. QTcF interval ≥ 460 ms on resting 12-lead ECG.
    3. Acute coronary syndrome, congestive heart failure, aortic dissection, cerebrovascular accident, or other Grade 3 or higher cardiovascular events occurring within six months prior to the first study dose.
    4. New York Heart Association (NYHA) functional classification ≥ Class II OR left ventricular ejection fraction (LVEF) <50%, OR other investigator-assessed high-risk structural heart diseases.
    5. Clinically uncontrolled hypertension.
  • Participants with autoimmune disorders or immunodeficiency conditions, or who have received allogeneic hematopoietic stem cell transplantation, or solid organ transplantation.

  • Asplenia, functional asplenia, or any condition resulting in absence or removal of the spleen.

  • Have any of the following serum virology findings:

    1. Positive HIV antibody test; OR

    2. Positive Treponema pallidum antibody; OR

    3. Active hepatitis B infection defined as:

      HBsAg positive AND HBV-DNA >500 IU/mL or above institutional detection limit if higher than standard threshold (only when the lower limit of detection threshold of the clinical trial institution is higher than 500 IU/mL)

    4. Active hepatitis C infection defined as: Anti-HCV positive AND HCV-RNA above institutional detection limit Note: Individuals receiving prophylactic antiviral therapies other than interferon are allowed to be enrolled.

  • Have uncontrolled seizures, central nervous system disorders, or psychiatric conditions resulting in loss of cognitive capacity.

  • Have a history within the past year of, or are currently experiencing, any other clinically significant uncontrolled medical conditions, including but not limited to cardiac, hepatic, pulmonary, renal, gastrointestinal, neurological, psychiatric, metabolic disorders.

  • Have received any blood products within three months prior to enrollment.

  • Require concomitant use of antiviral therapy OR have received antiviral medications within two weeks prior to the first administration of the study drug.

  • Have received any vaccination within four weeks prior to enrollment.

  • History of previous therapeutic HPV vaccination (individuals who have been immunized with licensed prophylactic HPV vaccines are not excluded).

  • Tattoos, scars, or active dermatologic lesions or rashes at the injection site that interfere with local safety assessments.

  • Currently receiving OR have received following doses of systemic corticosteroid therapy prior to the first administration of the investigational product:

    1. Long-term corticosteroid therapy: > 10 mg/day prednisone or equivalent within 30 days prior to the first study dose;
    2. Short-term corticosteroid therapy: ≥ 1 mg/kg/day prednisone or equivalent for ≥ 2 courses, each lasting >3 days, within 30 days prior to the first study dose.

Note: Topical, ocular, intra-articular, nasal, or inhaled corticosteroids are permitted.

  • Have a history of severe allergies or known allergic constitution.
  • Other conditions deemed unsuitable for study enrollment by the investigator.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Não randomizado
  • Modelo Intervencional: Atribuição sequencial
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Cohort A Dose Level 1

KDTV001:1 × 10^11 VP, IM, W0, W4, W12

KDTV001 Injection is a non-replicating adenovirus serotype 5 (Ad5)-based therapeutic HPV vaccine developed by Wuhan KadGeno Biotechnology Co., Ltd. It utilizes an engineered adenoviral vector expressing the HPV16/18/52 E6/E7 fusion protein under CMV promoter control, designed to inducing a robust cellular immune response that eradicates HPV-related lesions.

Experimental: Cohort A Dose Level 2

KDTV001: 3 × 10^11 VP, IM, W0, W4, W12

KDTV001 Injection is a non-replicating adenovirus serotype 5 (Ad5)-based therapeutic HPV vaccine developed by Wuhan KadGeno Biotechnology Co., Ltd. It utilizes an engineered adenoviral vector expressing the HPV16/18/52 E6/E7 fusion protein under CMV promoter control, designed to inducing a robust cellular immune response that eradicates HPV-related lesions.

Experimental: Cohort B Dose Level 1

KDTV001: 1 × 10^10 VP, IC, W0, W4, W12

KDTV001 Injection is a non-replicating adenovirus serotype 5 (Ad5)-based therapeutic HPV vaccine developed by Wuhan KadGeno Biotechnology Co., Ltd. It utilizes an engineered adenoviral vector expressing the HPV16/18/52 E6/E7 fusion protein under CMV promoter control, designed to inducing a robust cellular immune response that eradicates HPV-related lesions.

Experimental: Cohort B Dose Level 2

KDTV001: 3 × 10^10 VP, IC, W0, W4, W12

KDTV001 Injection is a non-replicating adenovirus serotype 5 (Ad5)-based therapeutic HPV vaccine developed by Wuhan KadGeno Biotechnology Co., Ltd. It utilizes an engineered adenoviral vector expressing the HPV16/18/52 E6/E7 fusion protein under CMV promoter control, designed to inducing a robust cellular immune response that eradicates HPV-related lesions.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Phase 1: Incidence of Any Adverse Events (AEs), Treatment related AEs (TRAEs) and Serious Adverse Events (SAEs) Following Investigational Treatment for the Duration of the Study
Prazo: From enrollment to 2 years after the first dose.

Percentage of participants with AE/TRAE/SAE in FAS population

From enrollment to 2 years after the first dose.
Phase 2: Percentage of Participants With No Evidence of Cervical HSIL on Histology and No Evidence of HPV-16 and HPV-18 and HPV-52 in Cervical Samples
Prazo: From enrollment to 36 weeks after the first dose.

Participants with no histologic (i.e., biopsies or excisional treatment) evidence of cervical HSIL, no evidence of HPV-16 and HPV-18 and HPV-52 at the Week 36 time frame, and participants in which excision or biopsy sample was not obtained between the initial dose up to Week 36 were considered to be responders. No evidence of HSIL was defined by histology as negative, squamous atypia, or low-grade intraepithelial lesion (LSIL). HPV testing will be performed using the cobas® assay and a second assay kit manufactured in China to identify HPV 52.

From enrollment to 36 weeks after the first dose.

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Phase 1: HPV clearance rates after dosing;
Prazo: From enrollment to 104 weeks after the first dose.

Incidence of Participants with no evidence of HPV-16 and HPV-18 and HPV-52 at Week 12, 24, and 36, and Week 52, 78, and 104 if the participants do not have excisional treatment. HPV testing will be performed using the cobas® assay and a second assay kit manufactured in China to identify HPV 52.

From enrollment to 104 weeks after the first dose.
Phase 2: The immunogenicity of KDTV001 injection;
Prazo: From enrollment to 52 weeks after the first dose.

Immunogenicity within 52 weeks after the first dose: cellular immune responses against E6/E7 of HPV16/18/52, including enzyme-linked immunospot (ELISPOT) assay and flow cytometry, etc.

From enrollment to 52 weeks after the first dose.
Companion biomarkers of KDTV001
Prazo: From enrollment to 52 weeks after the first dose.
  • HPV integration;
  • Patient HLA typing;
  • p16, HPV E6/E7 and Ki67 gene expression analysis as well as immune infiltration analysis, etc. of cervical tissues;
  • Cervical gene methylation level;
  • Cell-free Human Papillomavirus DNA (cfDNA-HPV), peripheral blood immune cell subsets, and related antibody production (e.g. peripheral blood antibodies to HPV16/18/52 E6/E7 and viral vector (Ad5)).
From enrollment to 52 weeks after the first dose.

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

6 de janeiro de 2026

Conclusão Primária (Estimado)

30 de novembro de 2027

Conclusão do estudo (Estimado)

30 de janeiro de 2029

Datas de inscrição no estudo

Enviado pela primeira vez

4 de novembro de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

13 de novembro de 2026

Primeira postagem (Real)

19 de novembro de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

19 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

13 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • KDTV001-101

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Sim

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .